← Back to headlines
Nuvation Bio and Eisai's Taletrectinib Application for NSCLC Accepted by EMA
The European Medicines Agency (EMA) has accepted the application from Nuvation Bio and Eisai for taletrectinib, a drug intended for the treatment of non-small cell lung cancer (NSCLC).
26 Mar, 21:26 — 26 Mar, 21:26
Sources
Showing 1 of 1 sources
Related Stories
US FDA Approves Breakthrough Pancreatic Cancer Drug Showing Improved Survival Rates
23m ago
Scarlet Fever Case Confirmed at Wellington School Prompting Health Alerts
47m ago
Netherlands murder rate hits record low while femicide figures remain unchanged
1h ago
Greece Intensifies Spraying Campaigns Amid West Nile Virus Surge in Attica
1h ago